{"id":5070,"date":"2021-10-25T13:31:45","date_gmt":"2021-10-25T13:31:45","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=5070"},"modified":"2025-11-26T14:51:24","modified_gmt":"2025-11-26T12:51:24","slug":"interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/","title":{"rendered":"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d’euros"},"content":{"rendered":"

[image_with_animation image_url=\u00a0\u00bb7012″ animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bb\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb img_link=\u00a0\u00bbhttps:\/\/www.bfmtv.com\/economie\/entreprises\/industries\/herve-affagard-cofondateur-et-directeur-general-de-maa-t-pharma-l-association-entre-la-modulation-du-microbiote-intestinal-et-ces-immunotherapies-vont-permettre-d-avoir-une-efficacite-accrue-des-traitements-anti-cancer_VN-202110250074.html\u00a0\u00bb]<\/p>\n","protected":false},"excerpt":{"rendered":"

[image_with_animation image_url=\u00a0\u00bb7012″ animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bb\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb img_link=\u00a0\u00bbhttps:\/\/www.bfmtv.com\/economie\/entreprises\/industries\/herve-affagard-cofondateur-et-directeur-general-de-maa-t-pharma-l-association-entre-la-modulation-du-microbiote-intestinal-et-ces-immunotherapies-vont-permettre-d-avoir-une-efficacite-accrue-des-traitements-anti-cancer_VN-202110250074.html\u00a0\u00bb]<\/p>\n","protected":false},"author":2,"featured_media":6987,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[],"category_press":[],"year_press":[],"class_list":["post-5070","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media-fr"],"acf":[],"yoast_head":"\nGood Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d'euros - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d'euros - 黑料社\" \/>\n<meta property=\"og:description\" content=\"[image_with_animation image_url=\u00a0\u00bb7012″ animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bb\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb img_link=\u00a0\u00bbhttps:\/\/www.bfmtv.com\/economie\/entreprises\/industries\/herve-affagard-cofondateur-et-directeur-general-de-maa-t-pharma-l-association-entre-la-modulation-du-microbiote-intestinal-et-ces-immunotherapies-vont-permettre-d-avoir-une-efficacite-accrue-des-traitements-anti-cancer_VN-202110250074.html\u00a0\u00bb]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-25T13:31:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T12:51:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/Website_BFMbusiness_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2362\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d’euros\",\"datePublished\":\"2021-10-25T13:31:45+00:00\",\"dateModified\":\"2025-11-26T12:51:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/\"},\"wordCount\":58,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/Website_BFMbusiness_logo.png\",\"articleSection\":[\"M\u00e9dia\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/\",\"name\":\"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d'euros - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/Website_BFMbusiness_logo.png\",\"datePublished\":\"2021-10-25T13:31:45+00:00\",\"dateModified\":\"2025-11-26T12:51:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/Website_BFMbusiness_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/Website_BFMbusiness_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d’euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d'euros - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/","og_locale":"fr_FR","og_type":"article","og_title":"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d'euros - 黑料社","og_description":"[image_with_animation image_url=\u00a0\u00bb7012″ animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bb\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb img_link=\u00a0\u00bbhttps:\/\/www.bfmtv.com\/economie\/entreprises\/industries\/herve-affagard-cofondateur-et-directeur-general-de-maa-t-pharma-l-association-entre-la-modulation-du-microbiote-intestinal-et-ces-immunotherapies-vont-permettre-d-avoir-une-efficacite-accrue-des-traitements-anti-cancer_VN-202110250074.html\u00a0\u00bb]","og_url":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/","og_site_name":"黑料社","article_published_time":"2021-10-25T13:31:45+00:00","article_modified_time":"2025-11-26T12:51:24+00:00","og_image":[{"width":2362,"height":2362,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/Website_BFMbusiness_logo.png","type":"image\/png"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d’euros","datePublished":"2021-10-25T13:31:45+00:00","dateModified":"2025-11-26T12:51:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/"},"wordCount":58,"commentCount":1,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/Website_BFMbusiness_logo.png","articleSection":["M\u00e9dia"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/","url":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/","name":"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d'euros - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/Website_BFMbusiness_logo.png","datePublished":"2021-10-25T13:31:45+00:00","dateModified":"2025-11-26T12:51:24+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/Website_BFMbusiness_logo.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/Website_BFMbusiness_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/fr\/interview-herve-affagard-introduction-en-bourse-la-biotech-lyonnaise-maat-pharma-espere-lever-entre-35-et-45-millions-deuros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"Good Morning Business- Introduction en Bourse : la biotech lyonnaise 黑料社 esp\u00e8re lever entre 35 et 45 millions d’euros"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/5070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=5070"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/5070\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/6987"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=5070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=5070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=5070"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=5070"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=5070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}